Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Axogen, Inc. (NASDAQ: AXGN) filings with the U.S. Securities and Exchange Commission, along with AI-assisted summaries to help interpret key disclosures. Axogen is a Minnesota-incorporated medical technology company focused on peripheral nerve repair and regeneration, and its filings offer detailed insight into financial performance, regulatory milestones, and corporate governance.
Through Axogen’s annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review audited and interim financial statements, risk factors, management’s discussion and analysis, and information on its portfolio of peripheral nerve repair products, including Avance (acellular nerve allograft-arwx), Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. These reports also discuss regulatory processes, reimbursement trends, and non-GAAP measures such as EBITDA and Adjusted EBITDA.
Current reports on Form 8-K capture material events, such as Axogen’s announcements regarding FDA review timelines and approval of the Biologics License Application for Avance, quarterly financial results, changes to executive compensation arrangements, and outcomes of annual shareholder meetings. Regulation FD disclosures within 8-K filings often furnish press releases and investor presentations related to earnings and regulatory updates.
Investors can also use this page to track proxy materials and shareholder vote results on matters like director elections, long-term incentive plans, advisory votes on executive compensation, and auditor ratification. Where available, Form 4 and other insider transaction filings can be consulted to monitor trading activity by directors and officers.
The platform’s AI-powered tools summarize lengthy filings, highlight important sections, and surface items such as Avance BLA developments, risk factor changes, and capital structure information, helping readers navigate Axogen’s SEC reporting more efficiently.
Axogen, Inc. entered into an underwriting agreement to sell 4,000,000 shares of its common stock at a public offering price of $31.00 per share, with underwriters holding a 30‑day option to buy up to an additional 600,000 shares. The shares are being sold under an automatic shelf registration and the offering is expected to close on January 23, 2026.
The company also signed a payoff letter for its term loan credit facility with Oberland Capital and affiliates, setting a final payoff amount of approximately $69.7 million if repaid on or before February 15, 2026. After the offering is completed and repayment conditions are met, Axogen expects to use a significant portion of the net proceeds to pay off the credit facility, which would terminate the loan and release all related liens.
Axogen, Inc. is conducting a public offering of 4,000,000 shares of common stock at $31.00 per share, with underwriters holding a 30‑day option to buy up to 600,000 additional shares. The company expects net proceeds of about $115.9 million (or $133.3 million if the option is fully exercised) and plans to use roughly $69.7 million to repay and terminate its Oberland credit facility, with the balance for working capital and capital spending.
Axogen reports preliminary 2025 revenue of about $225.2 million, up roughly 20.2% year over year, and fourth‑quarter revenue of about $59.9 million, up about 21.3%. Gross margin for 2025 and the fourth quarter is expected to be above 74%, including approximately $1.9 million in largely non‑cash one‑time costs tied to FDA approval milestones.
On December 3, 2025, the FDA approved Axogen’s Biologics License Application for Avance, an acellular nerve scaffold for specific sensory, mixed, and motor nerve indications, with certain uses granted under the accelerated approval pathway and subject to a confirmatory post‑marketing study.
Axogen is offering $85 million of common stock in a primary equity raise. The company has also granted underwriters a 30-day option to buy up to an additional $12.75 million of shares. Axogen currently intends to use a significant portion of the net proceeds to make an early payoff of its Oberland credit facility, with a final repayment amount expected to be approximately $69.7 million, which would terminate all obligations under that debt.
Alongside the financing, Axogen outlines strong preliminary 2025 results, with expected revenue of about $59.9 million for the fourth quarter and $225.2 million for the full year, increases of 21.3% and 20.2% versus 2024. Gross margin for 2025 is expected to be above 74%, despite about $1.9 million of one-time costs tied to FDA approval of its Avance biologic. The company ended 2025 with approximately $45.5 million in cash, cash equivalents, restricted cash and investments, up about $6.0 million from a year earlier.
The FDA approved Axogen’s Biologics License Application for Avance in December 2025, granting full approval for certain sensory nerve indications and accelerated approval for longer sensory and mixed and motor nerve repairs, subject to a confirmatory post-marketing study running through 2030 with a final report due in 2031.
Axogen, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer and sell common stock, preferred stock, debt securities, and warrants from time to time. The company may issue these securities in one or more offerings, separately or together, and on terms to be described in future prospectus supplements, with no limit on the aggregate amount registered under this shelf. Axogen states that net proceeds from any sales will generally be used for corporate purposes such as working capital and capital expenditures.
The prospectus also describes Axogen’s business as a leader in peripheral nerve repair, outlines its existing capital structure and anti‑takeover provisions, and explains generic terms for any future debt securities, warrants, and global securities. Each specific financing transaction will have its own prospectus supplement detailing pricing, terms, distribution method, and associated risks.
Axogen, Inc. reported that it has released preliminary, unaudited financial results for its fourth quarter and full year 2025. The company furnished these results through a press release dated January 12, 2026, attached as Exhibit 99.1 to this report. Axogen also posted an updated corporate presentation on its investor relations website and furnished it as Exhibit 99.2. Both the press release and the presentation are provided as “furnished,” not “filed,” meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
Axogen, Inc. director reports stock option exercises and share sales. On 12/16/2025, the reporting person exercised three non-qualified stock option grants for 5,000, 20,436 and 18,248 shares of Axogen common stock at exercise prices of $8.95, $6.30 and $7.04 per share. On the same date, they sold 5,000, 20,436 and 18,248 shares at a weighted average sale price of $29.312 per share, with individual sale prices ranging from $28.99 to $29.63. After these transactions, the reporting person directly beneficially owned 93,826 shares of Axogen common stock, and the reported option grants had zero derivative securities remaining.
Axogen, Inc. director stock transactions: On 12/16/2025, a director of Axogen, Inc. exercised employee stock options to acquire 18,248 shares of common stock at $7.04 per share and 21,825 shares at $6.95 per share. These exercises increased the director’s direct holdings to 46,653 shares.
On the same date, the director sold 18,248 shares and 21,825 shares at a weighted average sale price of $29.547 per share, and an additional 6,580 shares at $29.55 per share. After these transactions, the director held 0 shares of common stock directly and 43,651 employee stock options, which are exercisable for Axogen common stock.
Axogen, Inc. reported an equity transaction by its Chief Financial Officer. On 12/15/2025, the CFO exercised an employee stock option to acquire 14,812 shares of Axogen common stock at an exercise price of $8.27 per share. On the same date, the CFO sold 14,812 shares of common stock at a weighted average sale price of $29.8605 per share, leaving 31,376 shares of common stock beneficially owned directly after the transactions.
The derivative position tied to this option was reduced to zero following the exercise. The option related to 14,812 underlying shares of Axogen common stock and was scheduled to be fully vested by March 16, 2027 under a vesting schedule where 50% vested on March 16, 2025 and an additional 12.5% vested every six months thereafter.
Axogen, Inc. Chief Executive Officer Michael Dale reported selling 25,000 shares of the company’s common stock on 12/10/2025 at $30 per share. After this sale, he directly beneficially owns 63,537 shares of Axogen common stock.
Axogen, Inc. executive vice president and general counsel Marc Began reported a sale of company stock. On 12/11/2025, he sold 13,222 shares of Axogen common stock at $30 per share. After this transaction, he directly beneficially owns 18,285 shares of Axogen common stock.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
